Truscreen Market Update

7 March 2019

NZX Announcement

TruScreen Market Update

• TruScreen continues to implement the strategy to offer cervical cancer
screening solutions in developing nations
• Strategic partnership in progress in Russia and Africa
• Progress made in developing nations where 90% of deaths (~270,000
annual deaths) occur from cervical cancer
• Forecast FY results to 31 March 2019



Real time cervical cancer screening technology company TruScreen (NZX:TRU or “The
Company”) is pleased to provide a market update on its various commercial operations.

Russia Update

The Company has signed a new distribution agreement for the Russian market with
IMSystems JSC, which includes an initial pre-paid order for multiple TruScreen devices
and Single Use Sensors (SUS) of approximately NZD364,000.

IMSystems has extensive expertise in the distribution of medical equipment and devices
in Russia and has partnerships with global brands and manufacturers, including GE
Healthcare. Under the terms of the distribution agreement, IMSystems will set up
infrastructure to support marketing, product servicing and training.

TruScreen CEO Martin Dillon noted the distribution agreement is another step in gaining
wider market distribution in the Russian market where there are more than 44 million
women of cervical cancer screening age.

“Russia is a significant market opportunity for TruScreen given the lack of laboratory and
screening infrastructure, a growing middle class, geographically diverse population with
a large cervical cancer screening age population,” said Mr Dillon.

“Our agreement with IMSystems is important for the Company as it adds to the
momentum and market development we currently have in Russia. We are pleased that
the agreement includes pre-payment for their significant initial order, demonstrating
IMSystem’s commitment to TruScreen and confidence in our innovative technology.

“This distribution agreement continues to support our growth strategy to improve the
wellbeing of women in developing markets with the latest technology in cervical cancer
screening and provide real-time, accurate detection of pre-cancerous and cancer cells.”

Africa Update

As previously announced to the market, TruScreen was selected by the National Aids
Council of Zimbabwe to provide cervical cancer screening to HIV affected women in that
country and the program is about to be officially launched. These women are five (5)
times more likely to suffer from cervical cancer than non-HIV affected women (estimated
10.8 million women UNAIDS data 2017).

On 1 March 2019 Her Excellency Bronte Moules, Australia’s Ambassador to Zimbabwe
highlighted this program in her speech to dignitaries. Ambassador Moules said “Putting
outstanding research into practice is an important goal and is an example of the work of
TruScreen, which has a unique invention that uses optical and electrical bio feedback to
identify pre-cancerous changes in the cervix.”

Outlook

Revenue or Sales growth is expected to continue. The Company estimates that its full
year to 31 March 2019 product sales will be approximately NZ$2.2 million, a 175%
increase over the prior year and revenue will increase by 36% over the same period.

The result for the 31 March 2019 year is expected to be a loss of approximately NZ$3.5
million (2018 NZ$4.2 million) an improvement of 17%. This resulted from increased sales,
cost management and further investment made in developing new markets for the
TruScreen cervical cancer screening device.

Commenting on outlook, TruScreen CEO Martin Dillon said “We are making good
progress to achieve a number of our commercial goals for the FY20 financial year which
is to deepen our global footprint through our key partnerships, endorsements from Key
Opinion Leaders and Government adoption which in turn will enhance our distribution
networks.

The Company is executing on its strategic plan after accounting for all costs relating to
the in–house manufacturing facility in Australia. This has resulted in greater capacity to
produce 200 units per month and improvements in gross profit per device. The Company
is in the process of bringing high tech production and assembly in house and transferring
technology to key markets for domestic registration as a means of achieving further cost
and product efficiencies.”


- ENDS -

For more information visit www.TruScreen.com or contact:

TruScreen Investors
Martin Dillon Investor Relations
CEO TruScreen Phone: +61 2 9237 2805
martindillion@truscreen.com Truscreen@we-buchan.com


About TruScreen:
Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen-
ultra-video/

TruScreen’s real time cervical cancer technology utilises a digital wand which is placed
on the surface of the cervix to measure electrical and optical signals from the
surrounding tissue. A sophisticated proprietary algorithm framework distinguishes
between normal and abnormal (cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor
(SUS) is used for each patient to protect against cross-infection.

For more information, visit our website at www.truscreen.com